MX339852B - Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. - Google Patents

Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina.

Info

Publication number
MX339852B
MX339852B MX2011004816A MX2011004816A MX339852B MX 339852 B MX339852 B MX 339852B MX 2011004816 A MX2011004816 A MX 2011004816A MX 2011004816 A MX2011004816 A MX 2011004816A MX 339852 B MX339852 B MX 339852B
Authority
MX
Mexico
Prior art keywords
oxo
prolonged release
release formulations
pyrrolidine derivative
relates
Prior art date
Application number
MX2011004816A
Other languages
English (en)
Other versions
MX2011004816A (es
Inventor
Fanara Domenico
Berwaer Monique
Eeckman Frederic
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MX2011004816A publication Critical patent/MX2011004816A/es
Publication of MX339852B publication Critical patent/MX339852B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende Levetiracetam, Brivaracetam o Seletracetam como el ingrediente activo, la invención se refiere específicamente a una formulación de liberación prolongada.
MX2011004816A 2008-11-18 2009-11-17 Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. MX339852B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08105817 2008-11-18
EP09100312 2009-06-02
PCT/EP2009/065271 WO2010057870A1 (en) 2008-11-18 2009-11-17 Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative

Publications (2)

Publication Number Publication Date
MX2011004816A MX2011004816A (es) 2011-05-30
MX339852B true MX339852B (es) 2016-06-15

Family

ID=41381618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004816A MX339852B (es) 2008-11-18 2009-11-17 Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina.

Country Status (18)

Country Link
US (3) US10172805B2 (es)
EP (1) EP2358360B1 (es)
JP (2) JP5954890B2 (es)
KR (1) KR101689688B1 (es)
CN (2) CN102215829B (es)
AU (1) AU2009317280B2 (es)
BR (1) BRPI0921313A2 (es)
CA (1) CA2741041C (es)
DK (1) DK2358360T3 (es)
EA (1) EA019572B1 (es)
ES (1) ES2602604T3 (es)
HK (1) HK1159503A1 (es)
HU (1) HUE032275T2 (es)
IL (1) IL212447A (es)
MX (1) MX339852B (es)
PL (1) PL2358360T3 (es)
PT (1) PT2358360T (es)
WO (1) WO2010057870A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107243007A (zh) 2008-10-16 2017-10-13 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
DK2358360T3 (en) * 2008-11-18 2016-12-12 Ucb Biopharma Sprl EXTENDED release formulations comprising one 2-OXO-1 PYRROLIDIN DERIVATIVE
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
WO2011135430A1 (en) * 2010-04-29 2011-11-03 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
EP3127539A1 (en) * 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
CN111407738A (zh) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 一种布立西坦控释制剂及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327424A (ja) 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE69111287T2 (de) * 1990-04-18 1995-12-21 Asahi Chemical Ind Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung.
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
JPH10182438A (ja) * 1991-03-07 1998-07-07 Takeda Chem Ind Ltd 有核散剤
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
WO2004047718A2 (en) 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
CN101111230B (zh) * 2005-03-29 2010-05-19 赢创罗姆有限责任公司 包含对活性成分具有调节释放作用的小丸的多颗粒药用形式
WO2006125074A1 (en) * 2005-05-17 2006-11-23 Brown University Research Foundation Drug delivery formulations for targeted delivery
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
ES2444009T3 (es) * 2006-06-08 2014-02-21 Ucb Pharma, S.A. Co-cristales de pirrolidinonas
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
MX370905B (es) * 2006-08-31 2020-01-09 Adare Pharmaceuticals Inc Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
US9555006B2 (en) * 2007-09-21 2017-01-31 Evonik Roehm Gmbh PH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
WO2009102964A2 (en) * 2008-02-14 2009-08-20 Nordson Corporation Apparatus for testing containers, tray for holding cylinders and suction-basedchuck for robotic arm
PT2358361T (pt) * 2008-11-18 2016-11-18 Ucb Biopharma Sprl Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina
DK2358360T3 (en) * 2008-11-18 2016-12-12 Ucb Biopharma Sprl EXTENDED release formulations comprising one 2-OXO-1 PYRROLIDIN DERIVATIVE

Also Published As

Publication number Publication date
AU2009317280B2 (en) 2014-03-06
CA2741041A1 (en) 2010-05-27
PT2358360T (pt) 2016-11-15
JP2015120756A (ja) 2015-07-02
KR101689688B1 (ko) 2016-12-26
HUE032275T2 (en) 2017-09-28
CA2741041C (en) 2015-01-13
BRPI0921313A2 (pt) 2015-12-29
US10172805B2 (en) 2019-01-08
MX2011004816A (es) 2011-05-30
CN102215829A (zh) 2011-10-12
US20190142759A1 (en) 2019-05-16
CN102215829B (zh) 2014-12-10
DK2358360T3 (en) 2016-12-12
EP2358360A1 (en) 2011-08-24
KR20110089182A (ko) 2011-08-04
EA201100752A1 (ru) 2012-01-30
EP2358360B1 (en) 2016-09-14
US20110250282A1 (en) 2011-10-13
US20200085754A1 (en) 2020-03-19
JP5954890B2 (ja) 2016-07-20
EA019572B1 (ru) 2014-04-30
HK1159503A1 (en) 2012-08-03
AU2009317280A1 (en) 2010-05-27
WO2010057870A1 (en) 2010-05-27
ES2602604T3 (es) 2017-02-21
PL2358360T3 (pl) 2017-02-28
JP2012509357A (ja) 2012-04-19
IL212447A0 (en) 2011-06-30
CN104208714A (zh) 2014-12-17
IL212447A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
MX339852B (es) Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina.
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2009117130A3 (en) Extended release forumulation containing a wax
PT2076119E (pt) Composição solvente incluindo pelo menos dois solventes, e formulação fitossanitária que inclua a composição referida bem como um composto activo
EP2308867A3 (en) 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2010021607A3 (en) Pharmaceutical formulation
MX2007004294A (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion.
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2009100441A3 (en) Depot formulations
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2010049454A3 (en) Antimicrobial composition from copepods
TN2012000147A1 (en) 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
PL1842534T3 (pl) Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
IL193024A0 (en) Levetiracetam formulations and methods for their manufacture
EP2285357B8 (en) Pharmaceutical compositions comprising brivaracetam
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
WO2011122872A3 (ko) 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물 포함 조성물
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
WO2006056695A8 (fr) Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
MX2007013327A (es) Formulaciones de liberacion prolongada.
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.

Legal Events

Date Code Title Description
FG Grant or registration